A phase 2 study of sorafenib (BAY 43-9006) in metastatic renal cell cancer to the brain

Trial Profile

A phase 2 study of sorafenib (BAY 43-9006) in metastatic renal cell cancer to the brain

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2013

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Cancer metastases; Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Apr 2008 The expected completion date for this trial is now 1 Jun 2007.
    • 16 Apr 2008 Status changed from in progress to completed.
    • 10 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top